¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hodgkin's disease, lymphocyte depletion type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® Hodgkin's disease ÇÑ±Û È£ÁöŲº´
¼³¸í   
  ¾Ç¼º¸²ÇÁÁ¾ÀÇ ÇÑ ÇüÅÂÀÌ´Ù. È£ÁöŲº´Àº ¹æ»ç¼± Ä¡·á¿¡ ´ë´ÜÈ÷ ¿¹¹ÎÇØ¼­ ÃæºÐÇÑ ¾çÀÇ ¹æ»ç¼±À¸·Î ¿ÏÀüÇÑ ±ÙÄ¡Àû Ä¡·á°¡ °¡´ÉÇÏ´Ù.
¿µ¹® lymphocyte ÇÑ±Û ¸²ÇÁ±¸
¼³¸í   
  ¸é¿ª±â´ÉÀ» ´ã´çÇϴ ¼¼Æ÷. °ñ¼ö¿¡¼­ ¸¸µé¾îÁö¸ç, ¸²ÇÁ±¸´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷, B¸²ÇÁ¼¼Æ÷·Î ³ª´µ¾îÁö°Ô µÈ´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â(¸é¿ª¹ÝÀÀ 4¹øÇü µî) µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ°¨¿°¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ» ´ã´çÇÑ´Ù.
¿µ¹® non-Hodgkin lymphoma ÇÑ±Û ºñÈ£ÁöŲ ¸²ÇÁÁ¾
¼³¸í   
  ¸²ÇÁÁ¾Àº ¸²ÇÁÀý¿¡ »ý±ä ¾Ç¼º Á¾¾çÀ¸·Î ¹éÇ÷º´°ú´Â ´Ù¸£´Ù. ¹éÇ÷º´Àº °ñ¼ö¿¡¼­ »ý±ä ¸²ÇÁ±¸¼º ¾Ç¼ºÁ¾¾çÀÌÁö¸¸, ¸²ÇÁÁ¾Àº ¸²ÇÁÁ¶Á÷¿¡¼­ »ý±ä ¸²ÇÁ±¸¼º ¾Ç¼ºÁ¾¾çÀÌ´Ù. Å©°Ô ¸²ÇÁÁ¾Àº 2°¡Áö·Î ³ª´­ ¼ö Àִ µ¥, È£ÁöŲº´(Hodgkin's lymphoma)°ú ºñÈ£ÁöŲ¸²ÇÁÁ¾(non-Hodgkin's lymphoma)À¸·Î ³ª´­ ¼ö ÀÖ´Ù. ¶ÇÇÑ ºñÈ£ÁöŲ¸²ÇÁÁ¾Àº ¿©·¯ °¡ÁöÀÇ ¼¼Æ÷ÇüÅ¿¡ µû¶ó ³ª´©°í ÀÖ´Ù. ÀÌ º´Àº ´ÜÁö ¸²ÇÁÀý»Ó¸¸ ¾Æ´Ï¶ó Áö¶ó, °ñ¼ö, À̿ܠ´Ù¸¥ ±â°üÀ» Ä§¹üÇÔÀ¸·Î½á ¾Ç¼ºÀ̸ç, »ý¸í¿¡ Å« À§ÇùÀ» ÁØ´Ù. ¾Ç¼º¸²ÇÁÁ¾ÀÇ ÀÏÁ¾. ÀüÀÌÀÇ ÇüŰ¡ ´Ù¾çÇÏ¿©, ÁÖÀ§ ¸²ÇÁÀýÀ» °Ç³Ê¶Ù¾î ´Ù¸¥ ¸²ÇÁÀý·Î ÀüÀÌÇϱ⵵ ÇÑ´Ù. ¶ÇÇÑ ¼¼Æ÷ÀÇ ÇüÅ¿¡ µû¶ó ¿©·¯ °¡Áö Á¾·ù°¡ ÀÖÀ¸¸ç ´ë°³ Ä¡·á´Â ¹æ»ç¼±Ä¡·á¿Í È­Çпä¹ýÀ» º¹ÇÕÇÏ¿© »ç¿ëÇÑ´Ù.
  
  
¿µ¹® T-lymphocyte ÇÑ±Û Æ¼ ¸²ÇÁ±¸
¼³¸í   
  ¸²ÇÁ°è¼¼Æ÷(¸²ÇÁ±¸)´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷(T-cell), B¸²ÇÁ¼¼Æ÷(B-cell)·Î ³ª´µ¾îÁø´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º ¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º ¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±â´ÉÀ» ´ã´çÇÑ´Ù. T-¸²ÇÁ±¸´Â ¸é¿ª±â´É¿¡ °¡Àå Áß¿äÇÑ ¿ªÇÒÀ» Çϴ ¼¼Æ÷·Î¼­ ¼¼Æ÷¸é¿ªÀ» ´ã´çÇϸç B-cellÀÇ ÀÛ¿ëÀ» Á¶ÀýÇϴ ±â´Éµµ ÀÖ´Ù. °ñ¼ö¿¡¼­ »ý¼ºµÇ¾î °¡½¿»ù¿¡¼­ ¼º¼÷µÈ´Ù. Å©°Ô º¸Á¶T¼¼Æ÷(helper T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» º¸Á¶ÇÑ´Ù)¿Í T¼¼Æ÷(suppressor T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» ¾ïÁ¦ÇÑ´Ù)·Î ±¸ºÐµÇ¸ç À̵éÀº ¼¼Æ÷ Ç¥¸é¿¡ ºÐÆ÷Çϴ Ç׿ø¿¡ ÀÇÇØ¼­ ½Äº°µÉ ¼ö ÀÖ´Ù.
¿µ¹® infectious disease ÇÑ±Û °¨¿°º´
¼³¸í   
  ¹ÙÀÌ·¯½º·ÎºÎÅÍ ±â»ýÃæ Å©±â±îÁöÀÇ »ý¹°À» ¿øÀÎÀ¸·Î Çϴ º´. ¿øÀÎÀº Á¢ÃËÀü¿°¼ºÀ̸ç, º´¿ø¿¡¼­ °¨¿°µÇ´Â °æ¿ìµµ ÀÖ´Ù. °¨¿°À» ¿øÀαտ¡ µû¶ó ºÐ·ùÇϸ頹ÙÀÌ·¯½º, ¼¼±Õ, Å¬¶ó¹Ìµð¾Æ, ¸®ÄÏÂ÷, ¹ÌÄÚ¹ÚÅ׸®¿ò, °õÆÎÀÌ, ¿øÃæ, À±Ãæ, ¿ÜºÎ±â»ýÃæ °¨¿°À¸·Î ³ª´­ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Hodgkin¡¯s disease
    È£ÁöŲº´
  • depletion
    °í°¥
  • non-Hodgkin¡¯s lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • salt depletion
    ¿°·ù»ó½Ç, ¿°·ù°í°¥
  • atypical lymphocyte
    ºñÁ¤Çü¸²ÇÁ±¸
  • effector lymphocyte
    È¿°ú¸²ÇÁ±¸
  • killer lymphocyte
    »ìÇØ¸²ÇÁ±¸, ¼¼Æ÷µ¶¼º¸²ÇÁ±¸
  • lymphocyte
    ¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤ÀÎÀÚ
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • mixed lymphocyte culture test
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • depletion
    °í°¥
  • non-Hodgkin lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • lymphocyte
    ¸²ÇÁ±¸
  • tension type headache
    ±äÀåÇüµÎÅë
  • storage-type
    ÃàÀûÇü
  • type
    Çü, À¯Çü
  • blood type
    Ç÷¾×Çü
  • Borrmann type
    º¸¸£¸¸Çü
  • cellular type
    ¼¼Æ÷Çü
  • lepromatous type
    ³ªÁ¾Çü
  • scirrhous type
    °æÈ­Çü
  • anemia of chronic disease
    ¸¸¼ºº´ºóÇ÷
  • disease
    º´, Áúȯ, Áúº´
  • adult disease
    (¢¡life style disease) »ýȰ½À°üº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • depletion
    °í°¥
  • non-Hodgkin lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • atypical lymphocyte
    ºñÀüÇü¸²ÇÁ±¸
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤±â
  • effector lymphocyte
    ÀÛµ¿¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • killer lymphocyte
    ¼¼Æ÷µ¶¼º¸²ÇÁ±¸
  • lymphocyte
    ¸²ÇÁ±¸
  • leukocytoid lymphocyte
    ¹éÇ÷±¸¸ð¾ç¸²ÇÁ±¸
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
  • resident lymphocyte
    »óÁÖ¸²ÇÁ±¸
  • reticular lymphocyte
    ¸Á»ó¸²ÇÁ±¸
  • sensitized lymphocyte
    ¹Î°¨¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • T cell ; T lymphocyte ; thymus derived lymphocyte
    T¼¼Æ÷ ; T¸²ÇÁ? ; Èä¼±À¯·¡¸²ÇÁ?
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • hodgkins disease,lymphocyte predominance
    ¸²ÇÁ±¸ ÇöÀúÇü
  • B cell/lymphocyte
    B ¼¼Æ÷/¸²ÇÁ±¸
  • B lymphocyte
    B ¸²ÇÁ±¸
  • B-lymphocyte
    B ¸²ÇÁ±¸.
  • Bare lymphocyte syndrome
    ¹«Ç¥Áö¸²ÇÁ±¸ÁõÈıº
  • T cell/lymphocyte
    T ¼¼Æ÷/¸²ÇÁ±¸
  • T lymphocyte
    T ¸²ÇÁ±¸
  • T-lymphocyte
    T-Àӯı¸
  • anti-lymphocyte globulin
    ¸²ÇÁ±¸ Çױ۷κҸ°
  • antigen, lymphocyte defined (LD)
    ¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
  • granulocyte-monocyte-lymphocyte antigens
    °ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hodgkins disease,lymphocyte predominance
    ¸²ÇÁ±¸ ÇöÀúÇü
  • hodgkins disease,lacunar cell in
    ¿­°ø¼¼Æ÷
  • hodgkins disease,mixed cellularity
    È¥ÇÕ¼¼Æ÷Çü
  • hodgkins disease,nodular sclerosis
    °áÀý¼º °æÈ­¼º
  • hodgkins disease,reed-sternberg cell in
    ¸®À̵å-½ºÅ׸¥º£¸£±× ¼¼Æ÷
  • non-Hodgkins lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • non-hodgkins lymphoma
    ¸û¸ù¸û¸²ÇÁÁ¾(¡­ðþ)
  • depletion
    ºÎÁ·(Üôðë), °áÇÌ(ÌÀù¹), °í°¥(ͽÊä)
  • depletion
    ºÎÁ·, °áÇÌ, °í°¥.
  • magnesium depletion
    ¸¶±×³×½·°¨¼ÒÁõ(¡­Êõá´ñø).
  • oxygen deficiency =o. want, o. lack, o. deprivation, o. depletion
    »ê¼ÒºÎÁ·(¡­ÝÕðë), »ê¼Ò°áÇÌ(ß«áÈÌÀù¹).
  • oxygen depletion
    »ê¼Ò°áÇÌ.
  • oxygen deprivation =o. lack, o. depletion
    »ê¼Ò°áÇÌ(¡­ÌÀù¹), »ê¼ÒºÎÁ·(¡­ÝÕðë).
  • pure water depletion
    ¼ø¼öºÐ°í°¥(âíâ©ÝÂͽÊä)
  • simple sodium depletion
    ´Ü¼øNa<³ªÆ®·ý>ºÎÁ·.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Small lymphocyte
    ÀÛÀº¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ¼ÒÀӯı¸
  • Large lymphocyte
    Å«¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ´ëÀӯı¸
  • Medium-sized lymphocyte
    Áß°£¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ÁßÀӯı¸
  • Lymphocyte
    ¸²ÇÁ±¸
    [¿¾ ¿ë¾î] Àӯı¸
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷(Á¦1Çü»ç±¸¼¼Æ÷)
  • Regular type
    ±ÔÄ¢Çü
    [¿¾ ¿ë¾î] ±ÔĢġ¹Ð°áÇÕÁ¶Á÷
  • Muscular type of artery
    ±ÙÀ°Çüµ¿¸Æ
    [¿¾ ¿ë¾î] ±ÙÇüµ¿¸Æ
  • Muscular type of lymphatic vessel
    ±ÙÀ°Çü¸²ÇÁ°ü
    [¿¾ ¿ë¾î] ±ÙÇüÀӯİü
  • Muscular type of vein
    ±ÙÀ°ÇüÁ¤¸Æ
    [¿¾ ¿ë¾î] ±ÙÇüÁ¤¸Æ
  • Type B spermatogonium
    ´ÊÁ¤Á¶¼¼Æ÷
    [¿¾ ¿ë¾î] BÁ¤Á¶¼¼Æ÷
  • Anovulatory type
    ¹«¹è¶õÇü
    [¿¾ ¿ë¾î] ¹«¹è¶õÇü
  • Ovulatory type
    ¹è¶õÇü
    [¿¾ ¿ë¾î] ¹è¶õÇü
  • Irregular type
    ºÒ±ÔÄ¢Çü
    [¿¾ ¿ë¾î] ºÒ±ÔĢġ¹Ð°áÇÕÁ¶Á÷
  • Calcified hypertrophic type
    ¼®È¸È­ºñ´ëÇü
    [¿¾ ¿ë¾î] ¼®È¸È­ºñ´ëÇü
  • Fibrous type of lymphatic vessel
    ¼¶À¯Çü¸²ÇÁ°ü
    [¿¾ ¿ë¾î] ¼¶À¯ÇüÀӯİü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymyarian type
    ´Ù±ÙÀ°Çü
  • type specimen
    ±âÁØÇ¥º»
  • arthropod-borne disease
    ÀýÁöµ¿¹°¸Å°³Áúº´
  • Chagas' disease
    »þ°¡½ºº´
  • endemic disease
    dzÅ亴
  • enzootic disease
    µ¿¹°ÅäÂøº´
  • helminthic disease
    ¿¬ÃæÁúȯ
  • hookworm disease
    ±¸Ã溴
  • hydatid disease
    Æ÷Ãæº´
  • insect borne disease
    °ïÃæ¸Å°³Áúȯ
  • metazoal disease
    ÈÄ»ýµ¿¹°Áúȯ
  • parasitic disease
    ±â»ýÃæº´
  • protozoan disease
    ¿øÃæÁúȯ, ¿øÃ溴
  • tropical disease
    ¿­´ëº´, ¿­´ëÁúȯ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • meniscus depletion sedimentation equilibrium
    ¸Þ´Ï½ºÄ¿½º ¼Ò½Ç ħ°­ÆòÇü(á¼ã÷öØË½øÁû¬)
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸-À¯µµ(ë¯Óô) È­ÇÐÁÖ¼ºÀÎÀÚ(ûùùÊñËà÷ì×í­)
  • lymphocyte transformation
    ¸²ÇÁ±¸º¯Çü(ܨû¡)
  • mixed lymphocyte culture
    È¥ÇÕ(ûèùê)¸²ÆÄ±¸¹è¾ç(ÛÆå×)
  • small lymphocyte
    ¼Ò(á³)Àӯı¸
  • T lymphocyte
    T Àӯı¸
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • C-type particles
    C-Çü(û¡) ÀÔÀÚ(Ø£í­)
  • C-type virus
    "C-Çü(û¡) ¹ÙÀÌ·¯½º, (ÔÒ) C-type particles"
  • dehydrogenase-type mechanism
    µðÇÏÀ̵å·ÎÀú³×À̽ºÇü(úþ) ±âÀü(Ѧï®)
  • delayed-type hypersensitivity
    Áö¿¬Çü °ú¹ÎÁõ(òÀæÅû¡Î¦ÚÂñø)
  • immediate-type hypersensitivity
    Áï½ÃÇü °ú¹ÎÁõ(ñíãÁúþΦÚÂñø)
  • L-type structure
    L-Çü(úþ)±¸Á¶(ϰðã)
  • mixed-type inhibitor
    È¥ÇÕÇü ÀúÇØÁ¦(ûèùêúþîÁúªð¥)
  • plant-type ferredoxin
    ½Ä¹°Çü(ãÕÚªû¡) Æä·¹µ¶½Å
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Hodgkin's disease
    È£ÁîŲº´
  • water depletion
    Å»¼ö
  • non-Hodgkin lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • lymphocyte
    ¸²ÇÁ±¸
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • T lymphocyte
    T¸²ÇÁ±¸
  • bell type
    Á¾¸ð¾ç, Á¾Çü
  • intracanalicular type
    ¼Ò°ü³»Çü
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´ÜX¼±ÀåÄ¡
  • onion-skin type
    ¾çÆÄ²®Áú¸ð¾ç
  • phased linear array type
    À§»óÂ÷¼±Çü¹è¿­½Ä
  • RF coil type
    °íÁÖÆÄÄÚÀÏÀ¯Çü
  • split electrode type probe
    ºÐÇÒÀü±ØÅ½ÃËÀÚ
  • acquired heart disease
    ÈÄõ¼º½ÉÀåÁúȯ
  • Addison's disease
    ¾Öµð½¼º´
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
LD labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear...
HD Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ...
PMD Progressive Muscular Dystrophy; ÁøÇ༺ ±ÙÀÌ¿µ¾çÁõ
  Types of PMD(Progressive Muscular Dystroph...
TAPVR Total Anomalous Pulmonary Venous Return
  = TAPVC
  4 Types of TAPVR
&...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LD Lymphocyte-depletion
LPHD Lymphocyte predominance Hodgkin's disease
LPHD lymphocyte predominant Hodgkin Disease
NLPHD Nodular lymphocyte predominance Hodgkin's disease
ATD Acute tryptophan depletion
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Hodgkin's disease
    È£ÁîŲ º´, È£ÁöŲ º´, Hodgkin º´
    µ¿ÀǾî=malignant lym
  • non-Hodgkin lymphoma
    ºñÈ£ÁöŲ ¸²ÇÁÁ¾
  • depletion
    °í°¥, ºÎÁ·, °áÇÌ
    1. ÅÖ ºñ¿ì´Â ÀÛ¿ë ¶Ç´Â °úÁ¤. ¾×üÀÇ Á¦°Å, ƯÈ÷ Ç÷¾×. 2. Ç÷¾×ÀÇ °úÀ× »ó½Ç¿¡ ÀÇÇÑ ÇǰïÇÑ »óÅÂ.
  • phosphate depletion
    Àλ꿰 °í°¥
  • salt depletion
    ¿°·ù °í°¥
  • volume depletion state
    ¿ë·® °í°¥ »óÅÂ, ü¾× °áÇÌ »óÅÂ
  • B lymphocyte
    B ¸²ÇÁ±¸
    1. Èä¼± ºñÀÇÁ¸¼ºÀ¸·Î Èä¼±ÀÇ ¿µÇâÀ» ¹ÞÁö ¾Ê°í, Á¶Á÷À» À¯ÁÖÇÏ´Â ¸²ÇÁ±¸. ü¾×¼º ¸é¿ª¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Ç׿ø¿¡ ÀÇÇÑ ÀÚ±ØÀ¸·Î ¾×¼º Ç×ü¸¦ ÇÕ¼ºÇÏ´Â ÇüÁú±¸·Î µÈ´Ù. 2. Ç÷¾×, °ñ¼ö ¹× ¸²ÇÁÀý, ºñÀå, Æíµµ µî ¸²ÇÁÁ¶Á÷, ±×¸®°í ¼ÒÈ­°ü°è µîÀÇ ºñ¸²ÇÁ Á¶Á÷¿¡ ºÐÆ÷ÇÑ´Ù. ÀÎü Ç÷¾×ÀÇ 10-20% Â÷ÁöÇÑ´Ù. Ç׿ø µî¿¡ ÀÇÇØ Ȱ¼ºÈ­µÇ¸é ¸²ÇÁ¿©Æ÷ ³»¿¡¼­ ¸ð¼¼Æ÷ º¯È¯
  • B-lymphocyte
    B ¸²ÇÁ±¸
    Ç÷Áß Àӯı¸ÀÇ 5-15%¸¦ Â÷ÁöÇÏ¸ç ¼¼Æ÷ Ç¥¸é¿¡ ¸é¿ª ±Û·ÎºÎ¸°ÀÌ Á¸ÀçÇÑ´Ù. ÀÌµé ¸é¿ª ±Û·ÎºÎ¸°Àº Ç׿ø¿¡ ´ëÇÑ ¼ö¿ëü·Î ÀÛ¿ëÇÑ´Ù. Ç÷Áß B ¼¼Æ÷ÀÇ ´ëºÎºÐÀº Ç¥¸é¿¡ IgM°ú IgD¸¦ °®°í ÀÖÀ¸¸ç ¼Ò¼ö¿¡¼­ IgG, IgA ȤÀº IgE°¡ ¹ß°ßµÈ´Ù. ±×·¯³ª Á¡¸· µî¿¡¼­´Â IgA¸¦ °®°í ÀÖ´Â B¼¼Æ÷°¡ ¸¹ÀÌ ¹ß°ßµÈ´Ù.
  • bone marrow-derived lymphocyte
    °ñ¼ö À¯·¡ Àӯı¸
  • bursa-derived lymphocyte
    ÆÄºÎ¸®½Ã¿ì½º ³¶ À¯·¡ Àӯı¸
  • effector lymphocyte
    ÀÛµ¿ ¸²ÇÁ±¸
  • immunocompetent T lymphocyte
    ¸é¿ª Àû°Ý T Àӯı¸
  • lymphocyte
    Àӯı¸
  • lymphocyte defined antigen
    ¸²ÇÁ±¸ ±ÔÁ¤ Ç׿ø
  • lymphocyte migration
    Àӯı¸ À̵¿
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
lymphocyte depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
(12 Dec 1998)
lymphocyte lymphocyte A type of non-granular antibodies.
(09 Oct 1997)
cancer, hodgkin's disease A type of lymphoma (cancer of the lymphatic system). The most common symptom of Hodgkin's disease is a painless swelling in the lymph nodes in the neck, underarm, or groin. Hodgkin's disease is diagnosed when abnormal tissue is detected by a pathologist after a biopsy of an enlarged lymph node. Treatment usually includes radiation therapy or chemotherapy. Regular follow-up examinations are important after treatment for Hodgkin's disease. Patients treated for Hodgkin's disease have an increased risk of developing other types of cancer later in life, especially leukaemia.
(12 Dec 1998)
Hodgkin's disease <haematology, oncology> A human malgnant disorder of lymph tissue (lymphoma) that appears to originate in a particular lymph node and later spreads to the spleen, liver and bone marrow. It occurs mostly in individuals between the ages of 15 and 35. It is characterised by progressive, painless enlargement of the lymph nodes, spleen and general lymph tissue.
Giant cells, the Reed Sternberg cells, with mirror image nuclei are diagnostic. Immunological depletion, caused perhaps by the excessive growth of neoplastic histiocytes, occurs.
Four types of the disease are recognised depending on the relative predominance of various neoplastic derivatives of the lymphoid series. Pyrexia is often a feature of the disease.
Death often results from generalised immunological inability to respond to infections. If detected early, it has a high remission rate.
Staging: Ann Arbor classification; each stage is further classified as:, A no symptoms, B fever, sweats, weight loss.
Stage I - involvement of a single lymph-node region or extralymphatic site.
Stage II - two or more sites of involvement on the same side of the diaphragm.
Stage III - disease involvement on both sides of the diaphragm.
Stage IV - disseminated disease of extralymphatic organs, with or without lymph-node involvement.
Indicence: approximately 1,500 new cases per year in the UK.
(30 Mar 2000)
disease, hodgkin's A type of lymphoma (cancer of the lymphatic system). The most common symptom is painless swelling of the lymph nodes in the neck, underarm, or groin. Hodgkin's disease is diagnosed when abnormal tissue is detected by a pathologist after a biopsy of an enlarged lymph node. Treatment usually includes radiation therapy or chemotherapy. Regular follow-up examinations are important after treatment. Patients treated for Hodgkin's disease have an increased risk of developing other types of cancer later in life, especially leukaemia.
A disease of the lymph nodes named after the English physician Thomas Hodgkin (1798-1866) who discovered it.
(12 Dec 1998)
chloride depletion Excessive loss of sodium chloride from the body in urine, sweat, etc.; a cause of secondary dehydration.
Synonym: chloride depletion.
Water depletion, reduction in the total volume of body water; dehydration.
(05 Mar 2000)
salt depletion Excessive loss of sodium chloride from the body in urine, sweat, etc.; a cause of secondary dehydration.
Synonym: chloride depletion.
Water depletion, reduction in the total volume of body water; dehydration.
(05 Mar 2000)
salt-depletion crisis Severe illness resulting from loss of sodium chloride, usually in urine (i.e., salt-losing nephritis), in sweat following severe exercise in hot weather, or in intestinal secretions, as in cholera. Can occur as result of Addison's disease or Addisonian crisis; characterised by hypovolaemia, hypotension.
(05 Mar 2000)
salt depletion syndrome low salt syndrome
depletion 1. The act or process of emptying, removal of a fluid, as the blood.
2. Exhausted state which results from excessive loss of blood.
Origin: L. Deplere = to empty
(18 Nov 1997)
depletion method <molecular biology, technique> A lab technique to isolate mRNA molecules from a specific gene by hybridising all of the mRNA molecules from a cell to a specific segment of DNA. The one mRNA molecule type which actually sticks is the one looked for.
(09 Oct 1997)
depletion response Subnormal metabolic response to trauma in a person whose physiologic processes are already depressed by disease.
(05 Mar 2000)
cancer, lymphoma, hodgkin's A type of lymphoma (cancer of the lymphatic system). The most common symptom of Hodgkin's disease is a painless swelling in the lymph nodes in the neck, underarm, or groin. Hodgkin's disease is diagnosed when abnormal tissue is detected by a pathologist after a biopsy of an enlarged lymph node. Treatment usually includes radiation therapy or chemotherapy. Regular follow-up examinations are important after treatment for Hodgkin's disease. Patients treated for Hodgkin's disease have an increased risk of developing other types of cancer later in life, especially leukaemia.
(12 Dec 1998)
cancer, lymphoma, non-hodgkin's A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
Goldman-Hodgkin-Katz equation An equation derived to predict membrane potentials in terms of the membrane's permeability to ions and their concentrations on either side.
Synonym: constant field equation, Goldman-Hodgkin-Katz equation, GHK equation.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Hodgkin's disease
    È£ÁöŲ º´(¾Ç¼º À°¾ÆÁ¾Áß)
  • depletion
    °í°¥
  • lymphocyte
    ¸²ÇÁÅç(¼¼Æ÷)
  • type
    Çü,ŸÀÌÇÁ,ÀüÇü,ȰÀÚ,ÀÚü
  • C-type virus
    CÇü ¹ÙÀÌ·¯½º(¹ß¾Ï¼ºÀ¸·Î ¿©°ÜÁö°í ÀÖÀ½)
  • Gothic type
    °íµñ ȰÀÚü
  • Moon type
    (¿µ±¹ÀÎ °í¾ÈÀÚ À̸§¿¡¼­)¹®Å¸ÀÌÇÁ(¹®ÀÚ ½ÀµæÈÄÀÇ ½Ç¸íÀÚ¸¦ À§ÇÑ µµµå¶óÁø ¹®ÀÚÀÇ ¼­Ã¼,Àμâ¹ý)
  • Moon type
    ¸ÍÀοëÀÇ ¹®½Ä¼±ÀÚ(¿µ±¹ÀÎ W,Moon ¹ß¸í)
  • Roman letters(type)
    ·Î¸¸Ã¼(ȰÀÚ)
  • character type
    ¼º°Ý À¯Çü
  • cold type
    ÄݵåŸÀÌÇÁ(»çÁø.½ÄÀÚµî ȰÀÚ ÁÖÁ¶¸¦ ÇÏÁö ¾Ê´Â ½ÄÀÚ)
  • cold type system
    Äݵå ŸÀÌÇÁ ½Ã½ºÅÛ(³³È°ÀÚ³ª ¿­À» »ç¿ëÇÏÁö ¾Ê°í Çʸ§À» ÁÖü·ÎÇÑ »ç½ÄÈ­¿¡ ÀÇÇÑ Àμ⠰øÁ¤
  • condensed type
    °¡´Ã°í ±ä ȰÀÚ
  • display type
    Ç¥Á¦;±¤°í¿ëÀÇ ´ëÇü ȰÀÚ
  • foundry type
    ¼öÁ¶ÆÇ ȰÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á